efgartigimod PH20 SC in stage B

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Clinical Trial

Last updated: 1/2/2026

Developer

ARGX

argenx SE

Related Pipeline

Pemphigus Vulgaris

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Active Idiopathic Inflammatory Myopathy

Multifocal Motor Neuropathy (MMN)

Generalized Myasthenia Gravis